FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-028									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Walker Neal						2. Issuer Name and Ticker or Trading Symbol Aclaris Therapeutics, Inc. [ACRS]										eck all applic	ationship of Reportin all applicable) Director		10% O	wner
	`	ERAPEUTICS, 1	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/01/2020										below)	Officer (give title below) Presiden		Other (below)	specify
(Street) WAYNE (City)			19087 (Zip)		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)										fividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				n
		Tab	le I - Nor	n-Deriv	ative	e Se	curit	ies Ac	qu	ired,	Dis	posed o	f, or E	ene	eficiall	y Owned				
Da				Date	Transaction te onth/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year		Code (Instr.		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			Securitie Benefici Owned F	5. Amount of Securities Beneficially Owned Following Reported		vnership n: Direct r Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
										Code	v	Amount	(A)	or	Price	Transaci (Instr. 3	action(s)			(3 4)
Common	Stock			06/0	1/202	0				M		73,01	4	4	(1)	1,10	7,907	D		
Common	Stock			06/02	1/202	0				F ⁽²⁾		20,97	6	D	\$1.32	2 1,08	6,931	D		
		-	Table II -									osed of, onverti				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date,	4. Transaction Code (Instr. 8)				Ex	Date Ex piration onth/Da	Date		7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		ecurity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Ow For Oir Or (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Da:	ate cercisab		Expiration Date	Title	0 0	Amount or Number of Shares					
Restricted stock units	(1)	06/01/2020			M			73,014		(3)		(3)	Commo		73,014	\$0.00	73,01	5	D	

Explanation of Responses:

- 1. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
- 2. The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4.
- 3. The shares underlying these restricted stock units vest in two equal annual installments beginning on June 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.

Remarks:

/s/ Mark Ballantyne, Attorneyin-fact

** Signature of Reporting Person Date

06/03/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.